Literature DB >> 6690075

Mitoxantrone metabolism in the isolated perfused rat liver.

G Ehninger, B Proksch, F Hartmann, H V Gärtner, K Wilms.   

Abstract

The hepatobiliary pharmacokinetics of mitoxantrone, a new anthracenedione derivative, was studied in the isolated perfused rat liver. Mitoxantrone was administered in doses of 0.2 and 0.4 mg/kg body weight. Multiple bile samples were obtained for 4 hours. Mitoxantrone and three metabolites were separated by high-performance thin-layer chromatography (HPTLC) and measured at 610 nm. Following 0.2 mg mitoxantrone/kg body wt, 25.8% +/- 2.6% of the administered dose was excreted in the bile during 4 h, the major metabolite M1 accounting for 80% of this. After 0.4 mg mitoxantrone/kg body wt the amounts excreted were lower and light microscopic examination showed disseminated areas of cell necrosis.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6690075     DOI: 10.1007/bf00255910

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  5 in total

1.  Activity and stability of microsomal mixed function oxidase and NAD glycohydrolase in isolated perfused rat liver.

Authors:  K W Bock; W Fröhling; W Schlote
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1972       Impact factor: 3.000

2.  Clinical analysis for the anti-neoplastic agent 1,4-dihydroxy-5,8-bis((2-[(2-hydroxyethyl)amino]ethyl)-amino)9,10-anthracenedio ne dihydrochloride (NSC 301739) in plasma. Application of temperature control to provide selectivity in paired-ion high-performance liquid chromatography.

Authors:  D L Reynolds; L A Sternson; A J Repta
Journal:  J Chromatogr       Date:  1981-02-13

3.  Phase I clinical investigation of 1,4-dihydroxy-5,8-bis (( (2-[(2-hydroxyethyl)amino]ethyl) amino))-9,10-anthracenedione dihydrochloride (NSC 301739), a new anthracenedione.

Authors:  D D Von Hoff; E Pollard; J Kuhn; E Murray; C A Coltman
Journal:  Cancer Res       Date:  1980-05       Impact factor: 12.701

4.  Phase I clinical trial f mitoxantrone: a new anthracenedione anticancer drug.

Authors:  D S Alberts; K S Griffith; G E Goodman; T S Herman; E Murray
Journal:  Cancer Chemother Pharmacol       Date:  1980       Impact factor: 3.333

5.  The dominant role of the liver in plasma protein synthesis; a direct study of the isolated perfused rat liver with the aid of lysine-epsilon-C14.

Authors:  L L MILLER; C G BLY; M L WATSON; W F BALE
Journal:  J Exp Med       Date:  1951-11       Impact factor: 14.307

  5 in total
  7 in total

Review 1.  Mitoxantrone. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in the chemotherapy of cancer.

Authors:  D Faulds; J A Balfour; P Chrisp; H D Langtry
Journal:  Drugs       Date:  1991-03       Impact factor: 9.546

Review 2.  Pharmacokinetics and metabolism of mitoxantrone. A review.

Authors:  G Ehninger; U Schuler; B Proksch; K P Zeller; J Blanz
Journal:  Clin Pharmacokinet       Date:  1990-05       Impact factor: 6.447

3.  Pharmacology of mitoxantrone: mode of action and pharmacokinetics.

Authors:  D S Alberts; Y M Peng; G T Bowden; W S Dalton; C Mackel
Journal:  Invest New Drugs       Date:  1985       Impact factor: 3.850

4.  The pharmacokinetics and metabolism of mitoxantrone in man.

Authors:  G Ehninger; B Proksch; G Heinzel; E Schiller; K H Weible; D L Woodward
Journal:  Invest New Drugs       Date:  1985       Impact factor: 3.850

5.  Mitoxantrone use in breast cancer patients with elevated bilirubin.

Authors:  R T Chlebowski; L Bulcavage; I C Henderson; T Woodcock; R Rivest; R Elashoff
Journal:  Breast Cancer Res Treat       Date:  1989-12       Impact factor: 4.872

6.  Bile lipid secretion in isolated perfused rat liver. A model for metabolic studies.

Authors:  J C Henry; N Domingo; F Chanussot; H Lafont; J C Hauton; J P Cano
Journal:  Lipids       Date:  1987-01       Impact factor: 1.880

7.  A single-center, self-controlled, phase I clinical trial of mitoxantrone hydrochloride injection for lymph tracing for sentinel lymph node identification of breast cancer.

Authors:  Benlong Yang; Shuyue Zheng; Xiaoyan Huang; Jiajian Chen; Zhebin Liu; Guangyu Liu; Shujun Wang; Zhimin Shao; Jiong Wu
Journal:  Gland Surg       Date:  2021-03
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.